Overview

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Protgen Ltd
Treatments:
Gemcitabine